Hall Philip
The Pelvic Medicine Center, St Andrew's War Memorial Hospital, Brisbane, Australia.
Womens Health Rep (New Rochelle). 2024 May 17;5(1):444-452. doi: 10.1089/whr.2024.0026. eCollection 2024.
The study aimed to investigate the feasibility of a newly available topical gel in improving the symptoms of various vulvovaginal skin conditions (NCT05396261).
Fifty-two women with diagnosed lichen sclerosus, lichen simplex chronicus, or genitourinary syndrome of menopause participated in this prospective single-arm feasibility study. Consented patients applied the product daily internally and externally to the genital area for approximately 6 months (short-term) and optionally up to 2 years (long-term). Outcome measures included patient-rated symptoms, investigator-assessed clinical signs, and visual severity of pathology of these vulvovaginal conditions. Clinical outcomes, patient adherence to the treatment, and adverse events were assessed, and the statistical analysis was split according to short-term and long-term treatment.
The majority of patients enrolled in the study suffered from an uncontrolled disease (90.4%). All patients showed significant improvement in all patient-rated symptoms ( < 0.001), overall clinical signs ( < 0.001), and visual severity of pathology ( < 0.001) short-term. These favorable results were maintained from month 6 up to 2 years. Patient compliance was high, and no adverse events were reported with use of the investigational product.
This topical medical device could be an effective symptomatic management option for women suffering from various vulvovaginal conditions.
本研究旨在探讨一种新上市的外用凝胶改善各种外阴阴道皮肤疾病症状的可行性(NCT05396261)。
52名被诊断为硬化性苔藓、慢性单纯性苔藓或绝经泌尿生殖综合征的女性参与了这项前瞻性单臂可行性研究。同意参与的患者每天在生殖器区域内外使用该产品约6个月(短期),可选择使用长达2年(长期)。观察指标包括患者自评症状、研究者评估的临床体征以及这些外阴阴道疾病病理的视觉严重程度。评估临床结局、患者对治疗的依从性和不良事件,并根据短期和长期治疗进行统计分析。
参与研究的大多数患者患有未得到控制的疾病(90.4%)。所有患者在短期内在所有患者自评症状(<0.001)、总体临床体征(<0.001)和病理视觉严重程度(<0.001)方面均有显著改善。这些良好结果从第6个月持续到2年。患者依从性高,使用该研究产品未报告不良事件。
这种外用医疗器械可能是患有各种外阴阴道疾病女性有效的症状管理选择。